NanoMed Pharmaceuticals Inc.
This article was originally published in Start Up
The idea of delivering drugs encased in lipids was a popular one in the early days of the biotechnology industry but manufacturing problems pushed lipid-based drug delivery from favor. NanoMed Pharmaceuticals thinks it has found a way to get lipids to fulfill their potential as delivery vehicles, shielding the drugs they contain from cellular mechanisms responsible for drug resistance. The start-up aims to leverage its know-how to treat cancers notoriously resistant to chemotherapy.
You may also be interested in...
FDA is building a knowledge base in nanotechnology and testing its current regulatory procedures. But adapting to the new field could stress the agency's already tight resources and may damage its fragile credibility with the public.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.